JP2011516426A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516426A5 JP2011516426A5 JP2011502126A JP2011502126A JP2011516426A5 JP 2011516426 A5 JP2011516426 A5 JP 2011516426A5 JP 2011502126 A JP2011502126 A JP 2011502126A JP 2011502126 A JP2011502126 A JP 2011502126A JP 2011516426 A5 JP2011516426 A5 JP 2011516426A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- deuterium
- hydrogen
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 24
- 229910052805 deuterium Inorganic materials 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000008732 thymoma Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000010749 gastric carcinoma Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 0 *C(*)(COc1cc2c(Nc3cc(Cl)ccc3)ncnc2cc1OCC(*)(*)O*)O* Chemical compound *C(*)(COc1cc2c(Nc3cc(Cl)ccc3)ncnc2cc1OCC(*)(*)O*)O* 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4064708P | 2008-03-28 | 2008-03-28 | |
| US61/040,647 | 2008-03-28 | ||
| US15754909P | 2009-03-04 | 2009-03-04 | |
| US61/157,549 | 2009-03-04 | ||
| PCT/US2009/038701 WO2009121042A1 (en) | 2008-03-28 | 2009-03-27 | Quinazoline derivatives and methods of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011516426A JP2011516426A (ja) | 2011-05-26 |
| JP2011516426A5 true JP2011516426A5 (cg-RX-API-DMAC7.html) | 2012-05-24 |
Family
ID=40638034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011502126A Pending JP2011516426A (ja) | 2008-03-28 | 2009-03-27 | キナゾリン誘導体および治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090269354A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2011516426A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20110005828A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102083801A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009121042A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110053968A1 (en) | 2009-06-09 | 2011-03-03 | Auspex Pharmaceuticals, Inc. | Aminopyrimidine inhibitors of tyrosine kinase |
| US20110195066A1 (en) * | 2010-02-05 | 2011-08-11 | Auspex Pharmaceuticals, Inc. | Quinoline inhibitors of tyrosine kinase |
| CN102946880A (zh) * | 2010-04-23 | 2013-02-27 | 尼基制药公司 | 治疗胰腺癌的方法 |
| US9145390B2 (en) | 2011-03-03 | 2015-09-29 | Concert Pharmaceuticals, Inc. | Derivatives of pyrazole-substituted amino-heteroaryl compounds |
| WO2014028914A1 (en) * | 2012-08-17 | 2014-02-20 | Beta Pharma, Inc. | Deuterated icotinib derivatives |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| CN103536925B (zh) * | 2013-10-28 | 2015-07-01 | 中国医学科学院基础医学研究所 | 强心苷化合物在非小细胞肺癌治疗中的应用 |
| CN106188072A (zh) * | 2015-05-07 | 2016-12-07 | 刘文沛 | 氘代4-[(3-乙炔苯基)氨基]-6,7-苯-12冠-4-喹唑啉衍生物以及包含该衍生物的药物组合物 |
| JP2022515256A (ja) * | 2018-12-25 | 2022-02-17 | ソル － ゲル テクノロジーズ リミテッド | Ｅｇｆｒ阻害剤を含む組成物による皮膚障害の治療 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL259609A (cg-RX-API-DMAC7.html) * | 1959-12-31 | |||
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| ATE446955T1 (de) * | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| YU13200A (sh) * | 1999-03-31 | 2002-10-18 | Pfizer Products Inc. | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
| UA74803C2 (uk) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| DK1104760T3 (da) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
| CZ20031903A3 (cs) * | 2001-01-31 | 2004-07-14 | Pfizer Products Inc. | Amidové deriváty thiazolyl-, oxazolyl-, pyrrolyl- a imidazolyl karboxylových kyselin užitečné jako inhibitory isozymů PDE4 |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| RU2006146625A (ru) * | 2004-06-03 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Лечение иринотеканом (срт-11) и ингибитором рецептора эпидермального фактора роста (egfr) |
| CN101309917B (zh) * | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| CA2661223A1 (en) * | 2006-08-22 | 2008-02-28 | Concert Pharmaceuticals Inc. | 4-aminoquinazoline derivatives and methods of use thereof |
| WO2008030382A1 (en) * | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| US8343950B2 (en) * | 2006-12-15 | 2013-01-01 | Concert Pharmaceuticals, Inc. | Quinazoline derivatives and methods of treatment |
| US20090076042A1 (en) * | 2007-09-15 | 2009-03-19 | Protia, Llc | Deuterium-enriched erlotinib |
-
2009
- 2009-03-27 WO PCT/US2009/038701 patent/WO2009121042A1/en not_active Ceased
- 2009-03-27 KR KR1020107024204A patent/KR20110005828A/ko not_active Withdrawn
- 2009-03-27 CN CN2009801188299A patent/CN102083801A/zh active Pending
- 2009-03-27 US US12/413,510 patent/US20090269354A1/en not_active Abandoned
- 2009-03-27 JP JP2011502126A patent/JP2011516426A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6043935B2 (ja) | ピペラジノトリアゾール化合物及びその製造方法と製薬用途 | |
| JP2014525464A5 (cg-RX-API-DMAC7.html) | ||
| JP2007515413A5 (cg-RX-API-DMAC7.html) | ||
| CN109803972A (zh) | 1H-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂 | |
| CN109661394A (zh) | Fgfr4抑制剂、其制备方法与药学上的应用 | |
| JP2010501572A5 (cg-RX-API-DMAC7.html) | ||
| JP2013518089A5 (cg-RX-API-DMAC7.html) | ||
| NZ561609A (en) | 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters | |
| JP2017516784A5 (cg-RX-API-DMAC7.html) | ||
| JP2010528026A5 (cg-RX-API-DMAC7.html) | ||
| JP2012506381A5 (cg-RX-API-DMAC7.html) | ||
| Hassan et al. | Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2 (1H)-one scaffold | |
| JP2009513662A5 (cg-RX-API-DMAC7.html) | ||
| JP2011520770A5 (cg-RX-API-DMAC7.html) | ||
| Zhao et al. | Identification of 3-substituted-6-(1-(1H-[1, 2, 3] triazolo [4, 5-b] pyrazin-1-yl) ethyl) quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization | |
| JP4852605B2 (ja) | 放射線治療増強剤 | |
| JP2014005265A5 (cg-RX-API-DMAC7.html) | ||
| CN108341799B (zh) | 用于治疗癌症、病毒感染和肺病的新型吲哚衍生物 | |
| WO2006084197A3 (en) | Nitroxides for use in treating or preventing neoplastic disease | |
| RU2011153613A (ru) | Аминопиразол триазолотиадиазольные ингибиторы протеинкиназы с-мет | |
| CN115836069A (zh) | 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途 | |
| JP2012528186A5 (cg-RX-API-DMAC7.html) | ||
| JP2012528185A5 (cg-RX-API-DMAC7.html) | ||
| JP2015523349A5 (cg-RX-API-DMAC7.html) | ||
| JP2014005265A (ja) | ピラゾール置換アミノ−ヘテロアリール化合物の誘導体 |